Board meeting on Nov 4 to approve Q2 and H1 FY27 results

Results View source PDF Explain this filing

MARKSANS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹302.90

prior close

₹304.65

announcement price

After-mkt

timing

Nifty Microcap 250market-2.6%+1.1% vs market

Pharmaceuticals peers, median of 172sector-1.7%+0.2% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

+0.3

15m

-0.2

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5-2.6+1.1-1.7+0.2

Next day

-2.2-3.6+1.4-2.1-0.1

-5.3-5.8+0.5-3.4-1.9

-2.0-5.5+3.5-2.4+0.4

-1.3-3.8+2.6-1.1-0.2

+0.6pendingpending+0.1+0.6

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Marksans Pharma's Board of Directors will meet on November 4, 2026 to consider and approve unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026. The trading window for designated persons is closed from October 1, 2026 till November 6, 2026.

Likely market impact

Routine board meeting intimation ahead of Q2 FY27 earnings. Watch for results on Nov 4.